Please login to the form below

Not currently logged in
Email:
Password:

major depressive disorder

This page shows the latest major depressive disorder news and features for those working in and with pharma, biotech and healthcare.

Sage surges after depression drug gets rapid path to approval

Sage surges after depression drug gets rapid path to approval

SAGE-217 is being tested in post-partum depression (PPD) that affects mother after childbirth as well as major depressive disorder (MDD), for which Sage reported positive phase 2 results last ... SAGE-217, if successfully developed and approved, may

Latest news

  • Daily Brief Daily Brief

    With about 30% of patients with major depression failing to respond to currently available antidepressants1, treatment-resistant depression represents a major public health need," said Husseini K. ... Esketamine received Breakthrough Therapy Designations

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    Despite a clinical efficacy and safety package with data from more than 30 clinical trials and around 1, 500 patients with major depressive disorder (MDD), the FDA has said it wants

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    First approved in 2015, Rexulti is currently available as an adjunctive therapy for adults with major depressive disorder as well as for schizophrenia and after a slow start, has seen its ... Abilify. Lundbeck and Otsuka are also evaluating the drug in a

  • FDA approves first substance use mobile medical application FDA approves first substance use mobile medical application

    More therapy tools means a greater potential to help improve outcomes, including abstinence, for patients with substance use disorder.”. ... However, Pear’s development pipeline does include a version of the app specifically for opioid use disorder,

  • Lundbeck partners with 23andMe on first-of-its-kind study Lundbeck partners with 23andMe on first-of-its-kind study

    The US project will involve 25, 000 patients and combine data from genetics, cognitive tests and online surveys to explore how genetics is related to major depressive disorder (MDD), bipolar depression

More from news
Approximately 6 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Leo has its eyes on the prize Leo has its eyes on the prize

    condition and the promise of major therapeutic breakthroughs. ... major depressive disorder and iron-deficiency anaemia.

  • Pharma deals continue to slide Pharma deals continue to slide

    74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase II oral kappa opioid receptor antagonist for adjunctive treatment of major depressive disorder.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics